Search Results

February 2022 Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder "Jan 27, 2022 07:00am Septerna wants to spark a second golden age in G-protein-coupled

of the New Center of Excellence for Structural Cell Biology Monash Scholars Ranked in Global Top 1% Septerna 2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers GPCR drugmaker Septerna

commercial R&D executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan Septerna landscape The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2024 Septerna

Industry News Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted

-1s like Ozempic are among the most important drug breakthroughs ever Goldman-backed drug developer Septerna

GPCR Industry News Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery

the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) Septerna

in Inversago patent Orion Biotechnology will be attending BIO 2024 Antiverse is attending BIO 2024 Septerna

Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea Septerna

Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update Septerna

Shows Potential for Treatment of Cannabis Use Disorder Reproducibility of Tanso Biosciences' GPCR Assay Septerna

characterization in drug discovery Confo Therapeutics Appoints Stephen Dowd As Chief Business Officer Septerna

Structural insight into the selective agonist ST1936 binding of serotonin receptor 5-HT6 Industry News Septerna

Biagon Officially Incorporated In The State Of Illinois Septerna divulges new TSHR antagonists for hyperthyroidism

Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023 Septerna

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Second Quarter 2024 Financial Results on August 8, 2024 Dynamic nature of G-protein coupled receptors Septerna

., as Senior Vice President of Medical Affairs Septerna to Participate in the Jefferies Global Healthcare

mellitus therapy Industry News OMass Therapeutics Welcomes Melissa Faris as Chief Business Officer Septerna

approval of insomnia drug in Japan Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s Septerna

reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity Septerna

through Structural Biology Industry News INV-347 by Inversago Pharma for Obesity: Likelihood of Approval Septerna

the Year from Locust Walk Omass Therapeutics 2022 Review Sosei hooks millions from Eli Lilly alliance Septerna

Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024 Nasdaq debutante Septerna

. · Septerna: closed a $100 Million USD Series A round to develop small molecule drugs against